Dynamics of vitamin K antagonist and new oral anticoagulants use in atrial fibrillation: a Danish drug utilization study

Summary Background Detailed data on real‐life utilization of vitamin K antagonists (VKAs) and new oral anticoagulants (NOACs) in atrial fibrillation are sparse. Objectives To describe the dynamics of VKA and NOAC use: that is, (i) how patients moved in and out of, as well as between, use of VKAs and...

Full description

Saved in:
Bibliographic Details
Published in:Journal of thrombosis and haemostasis 2014-09, Vol.12 (9), p.1413-1418
Main Authors: Pottegård, A., Poulsen, B. K., Larsen, M. D., Hallas, J.
Format: Article
Language:English
Subjects:
Administration, Oral
Aged
Aged, 80 and over
anticoagulants
Anticoagulants - administration & dosage
Atrial Fibrillation - drug therapy
atrial fibrilliation
Cohort Studies
coumarins
dabigatran
Databases, Factual
Denmark
Drug Utilization
Female
Humans
Kaplan-Meier Estimate
Male
Medication Adherence
Middle Aged
Physicians
Practice Patterns, Physicians
Registries
Vitamin K - antagonists & inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Background Detailed data on real‐life utilization of vitamin K antagonists (VKAs) and new oral anticoagulants (NOACs) in atrial fibrillation are sparse. Objectives To describe the dynamics of VKA and NOAC use: that is, (i) how patients moved in and out of, as well as between, use of VKAs and NOACs; (ii) how patients adhered to treatment; and (iii) which type of prescriber initiated, maintained, and changed treatment with VKAs and NOACs. Methods We conducted a drug utilization study in the region of southern Denmark (population 1.2 million) using prescription data. We included all subjects using VKAs or NOACs during the period of August 22, 2011, through June 30, 2013, restricted to subjects with a diagnosis of atrial fibrillation. Results We identified 20 911 subjects, of whom 20 769 and 1639 used VKAs and NOACs, respectively. The number of VKA users was stable at ~ 14 000 subjects during the study period, whereas the number of NOAC users increased to 903. The majority of NOAC users had previously used VKAs (n = 974), whereas 389 anticoagulant‐naïve users initiated NOAC therapy. Among the latter, 51.2% had changed to VKAs within 6 months. 57.3% of VKA users were initiated by a hospital physician, whereas maintenance treatment was predominantly handled by the patient's general practitioner (97.6%). Switches from NOAC to VKA were initiated by a general practitioner in 69.2% of the cases. For users of NOACs, these numbers were 73.5%, 94.0%, and 63.3%. Conclusions A large proportion of NOAC users switch to a VKA within a short time frame. The reasons for this are not clear.
ISSN:1538-7933
1538-7836
1538-7836
DOI:10.1111/jth.12662